Details of Drug

Details of Drug

 Drug General Information (ID: D0306)
  Drug Name
Cetuximab
  Drug Type Monoclonal antibody
  Drug Synonymous
Erbitux; Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN); novel EGFR mAb inhibitors
    Click to Show/Hide
  Disease Class 2B91: Colorectal cancer
  Therapeutic Class Antineoplastics
  External Link
TTD ID D0N5OV

Drug-Drug Interaction Network
  Sunburst Graph
AM006  Pharmacodynamic additive effects
BM043  Additive immunosuppressive effects
BM044  Additive myelosuppressive effects
BM047  Additive thrombogenic effects
BM066  Increased risk of hypomagnesemia
BM075  Increased risk of photosensitivity reactions
BM109  Increased risk of other adverse reactions (Unspecific)
  Relation Graph
 Full list of drugs interacting with Cetuximab
      Pharmacodynamic additive effects
   Additive immunosuppressive effects Drug Num:  3
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0260
 
Carboplatin
 
C6H12N2O4Pt
 
426756 
Moderate    Inter Info   
[6], [7]
D1174
 
Omacetaxine mepesuccinate
 
C29H39NO9
 
285033 
Moderate    Inter Info   
[15]
D1193
 
Oxaliplatin
 
C8H14N2O4Pt
 
9887053 
Moderate    Inter Info   
[6], [7]
   Additive thrombogenic effects Drug Num:  1
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D1569
 
Thalidomide
 
C13H10N2O4
 
5426 
Major    Inter Info   
[3], [4], [5]
   Increased risk of hypomagnesemia Drug Num:  6
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0458
 
Dexlansoprazole
 
C16H14F3N3O2S
 
9578005 
Moderate    Inter Info   
[10]
D0603
 
Esomeprazole
 
C17H19N3O3S
 
9568614 
Moderate    Inter Info   
[10]
D0892
 
Lansoprazole
 
C16H14F3N3O2S
 
3883 
Moderate    Inter Info   
[10]
D1179
 
Omeprazole
 
C17H19N3O3S
 
4594 
Moderate    Inter Info   
[10]
D1222
 
Pantoprazole
 
C16H15F2N3O4S
 
4679 
Moderate    Inter Info   
[10]
D1373
 
Rabeprazole
 
C18H21N3O3S
 
5029 
Moderate    Inter Info   
[10]
   Increased risk of photosensitivity reactions Drug Num:  5
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0062
 
Aminolevulinic acid
 
C5H9NO3
 
137 
Major    Inter Info   
[1], [2]
D0063
 
Aminolevulinic acid (topical)
 
C5H9NO3
 
137 
Moderate    Inter Info   
[6], [7], [8]
D1028
 
Methoxsalen
 
C12H8O4
 
4114 
Moderate    Inter Info   
[6], [12], [1], [13], [14]
D1033
 
Methyl aminolevulinate (topical)
 
C6H11NO3
 
157922 
Moderate    Inter Info   
[6], [7], [8]
D1691
 
Verteporfin
 
C82H84N8O16
 
11980904 
Moderate    Inter Info   
[7], [12], [1], [16]
   Increased risk of other adverse reactions (Unspecific) Drug Num:  3
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0249
 
Capecitabine
 
C15H22FN3O6
 
60953 
Moderate    Inter Info   
[6], [7], [9]
D0675
 
Fluorouracil
 
C4H3FN2O2
 
3385 
Moderate    Inter Info   
[6], [7], [9]
D0789
 
Idelalisib
 
C22H18FN7O
 
11625818 
Moderate    Inter Info   
[11]
References
1 Product Information. Nulibry (fosdenopterin). Origin Biosciences Inc, Boston, MA.
2 Product Information. Gleolan (aminolevulinic acid). NX Development Corp, Lexington, KY.
3 Figg WD, Arlen P, Gulley J, et al. "A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer." Semin Oncol 28(4 Suppl 15) (2001): 62-6. [PMID: 11685731]
4 Fine HA, Wen PY, Maher EA, et al. "Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas." J Clin Oncol 21 (2003): 2299-304. [PMID: 12805330]
5 Zangari M, Siegel E, Barlogie B, et al "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy." Blood 100 (2002): 1168-71. [PMID: 12149193]
6 Cerner Multum, Inc. "Australian Product Information.".
7 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
8 Product Information. Metvixia (methyl aminolevulinate topical). Galderma Laboratories Inc, Cranbury, NJ.
9 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
10 FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs).".
11 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
12 Multum Information Services, Inc. Expert Review Panel.
13 Product Information. Oxsoralen (methoxsalen). ICN Pharmaceuticals Inc, Costa Mesa, CA.
14 Product Information. Uvadex (methoxsalen). Therakos Inc, Exton, PA.
15 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
16 Product Information. Visudyne (verteporfin) Valeant Pharmaceuticals, Costa Mesa, CA.